Comparing a biosimilar to Enbrel for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This trial tests if a new biosimilar called MB04 works as well as the standard drug Enbrel for people with moderate to severe rheumatoid arthritis. Participants will keep taking methotrexate while being assigned to one of the two drugs to see how they compare.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with rheumatoid arthritis for at least 6 months but no more than 15 years.
- You have moderate to severe arthritis with at least 6 swollen joints and 6 tender joints, and certain blood test results.
- You have been taking a stable dose of methotrexate (10 to 25 mg weekly) for at least 12 weeks.
- You have been on a stable dose of prednisone (10 mg or less per day) for at least 4 weeks if you use it.
- You have not taken any biologic or targeted DMARD drugs before.
- You do not have active infections, recent cancer, or other inflammatory joint diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine called VDJ001 for people with moderate to severe rheumatoid arthritis who are already taking methotrexate. The goal is to see if VDJ001 helps reduce joint pain and swelling better than a placebo.
This trial looks at how two types of rheumatoid arthritis (RA) medications affect patients. It aims to compare anti-TNF drugs with other RA drugs to see if one type is better.
This early-stage study tests a new injectable medicine (KT501) for people with moderate to severe rheumatoid arthritis who have not responded well enough to other treatments and have specific antibodies in their blood. It aims to see how safe and well-tolerated the drug is.
This trial aims to find out if a simple blood test (biomarker) can show whether a lower dose of rituximab will work for people with rheumatoid arthritis. If successful, it could help patients maintain good results with less medicine and fewer side effects.
This trial tests an investigational drug called JAB-8263 for people with active rheumatoid arthritis. It aims to see if the drug can help reduce inflammation and improve symptoms.
This trial tests a new medication (BMS-986454) for people with rheumatoid arthritis who haven't responded well enough to methotrexate. It aims to see if the drug is safe and how it works in the body.
Hear when a new Rheumatoid Arthritis (RA) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.